Recombinant Proteins

Recombinant Proteins(重组蛋白)

Recombinant proteins are a new combination of genes that forms DNA. Recombinant DNA technology allows for the production of wild type and modified human and mammalian proteins at bulk quantities. Recombinant proteins are made from cloned DNA sequences which usually encode an enzyme or protein with known function

Recombinant proteins are made through genetic engineering, also called gene splicing or recombinant DNA technology. By putting human, animal or plant genes into the genetic material of bacteria, mammalian or yeast cells, these microorganisms can be used as factories or producers to make proteins for medical, academic and research uses.

A vector is simply a tool for manipulating DNA and can be viewed as a "transport vehicle" for the production of proteins from specific DNA sequences cloned into them. Purification and expression of a protein can sometimes be quite complicated & time-consuming, therefore an additional tag is used in addition to the specific DNA sequence which will facilitate the purification & expresion of the recombinant protein.

Recombinant Proteins are proteins that their DNA that has been created artificially. DNA from 2 or more sources which is incorporated into a single recombinant molecule. The DNA is first treated with restriction endonuclease enzyme which the ends of the cut have an overhanging piece of single-stranded DNA. These are called "sticky ends" because they are able to base pair with any DNA molecule containing the complementary sticky end. DNA ligase covalently links the two strands into 1 recombinant DNA molecule.

Recombinant DNA molecule must be replicated many times to provide material for analysis & sequencing. Producing many identical copies of the same recombinant DNA molecule is called cloning. Cloning is done in vitro, by a process called the polymerase chain reaction (PCR). Cloning in vivo can be done in unicellular microbessuch as E. coli, unicellular eukaryotes like yeast and in mammalian cells grown in tissue culture.

Recombinant DNA must be taken up by the cell in a form in which it can be replicated and expressed. This is achieved by incorporating the DNA in a vector. A number of viruses (both bacterial and of mammalian cells) can serve as vectors.

Recombinant DNA is also sometimes referred to as chimera. When combining two or more different strands of DNA.There are 3 different methods by which Recombinant DNA is made. 1. Transformation, 2. Phage-Transfection 3.Yeast, Plant & Mammalian Transformation. When using the method of transformation one needs to select a piece of DNA to be inserted into a vector, cut a piece of DNA with a restriction enzyme and ligate the DNA insert into the vector with DNA Ligase. The insert contains a selectable marker which allows for identification of recombinant molecules. An antibiotic marker is used in order to cause death for a host cell which does not contain the vector when exposed to a certain antibiotic.

Trasnformation is the insertion of the vector into the host cell. The host cells are prepared to take up the foreign DNA. Selectable markers are used for antibiotic resistance, color changes, or any other characteristic which can distinguish transformed hosts from untransformed hosts. Yeast, Plant & Mammalian Transformation is done by micro-injecting the DNA into the nucleus of the cell being transformed. Phage-Transfection process, is equivalent to transformation except for the fact that phage lambda or MI3 is used instead of bacteria.

These phages produce plaques which contain recombinant proteins which can be easily distinguished from the non-recombinant proteins by various selection methods.

Significant amounts of recombinant protein are produced by the host only when expression genes are added. The Protein’s expression depends on the genes which surround the DNA of interest, this collection of genes act as signals which provide instructions for the transcription and translation of the DNA of interest by the cell. These signals include the promoter, ribosome binding site, and terminator.

The recombinant DNA is inserted into expression vectors which contain the promoter, ribosome binding site, and terminator.

In prokaryotic systems, the promoter, ribosome binding site, and terminator have to be from the same host since the bacteria is unlikely to understand the signals of human promoters and terminators. The designated gene must not contain human introns since the bacteria does not recognize it and this results in premature termination, and the recombinant protein may not be processed correctly, be folded correctly, or may even be degraded.

The peptide sequence can be added as an extension at the N-terminal. Researchers can select the specific purification system which they would like to use. The unique vectors available contain several features needed for the production of bulk quantities of the target protein. The peptide sequence is usually placed in the vector so that it is designed to be a point of attack for a specific protease. Thus, after the recombinant protein is expressed and extracted from bacteria, specific peptide extension can be used to purify the protein and subsequently removed from the target protein to generate a nearly natural sequence on the final product.

6 or more consistent Histidine residues act as a metal binding site for recombinant protein purification and expression. The hexa-His sequence is called a His-Tag sequence which can be placed on the N-terminal of a target protein by using vectors from various commercial molecular biology companies. The His-Tag contains a cleavage site for a specific protease. His-Tag recombinant proteins are purified by Metal Chelate Affinity Chromatography such as nickel ion columns that are used as the heavy metal ion and the His-Tag protein is eluted from the metal-chelate column with Histidine or imidazole. Then the purified His-Tag protein is treated with the specific protease to cleave off the His-Tag or not if the tag doesn’t affect the active site of the protein.

Proteins have metal binding sites which can be used for the purification of recombinant and natural proteins. This type of purification is rather simple when using a gel bead which is covalently modified so that it displays a chelator group for binding a heavy metal ion like Ni2+ or Zn2+. The chelating group on the gel bead contains a small amount of the ligands needed to hold the metal ion. So when the protein’s metal binding site finds the heavy metal, it will bind by providing the ligands from its metal binding site to attach to the metal ion displayed on the chelator location of the gel bead. This purification method is quite identical to affinity chromatography when purifying metal-binding class of proteins.

研究方向

Recombinant Proteins 相关产品(2687)

  • GC72366 structure
    GC72366Volociximab
    CAS: 558480-40-3
    纯度: >95.50%

    Volociximab(M200)是一种嵌合的人/小鼠IgG4抗体IIA1,靶向整合素α5β1(EC50=0.2nM)。

  • GC72461 structure
    GC72461Rovelizumab
    CAS: 339086-79-2
    纯度: >97.00%

    Rovelizumab是一种人源化单克隆白整合素抗体。

  • GC72775 structure
    GC72775SIRT6-IN-2
    CAS: 891002-11-2
    纯度: >99.00%

    SIRT6-IN-2(化合物5)是一种选择性SIRT6抑制剂(IC50:34μM)。

  • GC72827 structure
    GC72827RK-9123016
    CAS: 955900-27-3
    纯度: >99.00%

    RK-9123016是SIRT2的强效抑制剂。

  • GC73079 structure
    GC73079Datopotamab deruxtecan
    CAS: 2238831-60-0
    纯度: >98.00%

    Datopotamab deruxtecan (ds - 1062;Dato-DXd是一种滋养细胞表面抗原2 (TROP2)导向的抗体-药物偶联物(ADC)。

  • GC73328 structure
    GC73328ODN TTAGGG sodium
    纯度: >99.00%

    ODN TTAGGG sodium,抑制性寡核苷酸(ODN),是一种TLR9, AIM2和cGAS拮抗剂。

  • GC73363 structure
    GC73363Antitumor agent-81
    CAS: 2765180-17-2
    纯度: >98.00%

    Antitumor agent-81(化合物5a)是一种低细胞毒性的P62-RNF168激动剂,可增强P62和RNF168之间的相互作用。

  • GC73519 structure
    GC73519BT200 sodium
    纯度: >98.00%

    BT200 sodium,适配体BT100的聚乙二醇化形式,抑制von Willebrand因子(VWF)与血小板糖蛋白GPIb的结合,预防动脉血栓形成。

  • GC73703 structure
    GC73703Sirtuin-1 inhibitor 1
    CAS: 945114-10-3
    纯度: >98.00%

    Sirtuin-1 inhibitor 1(化合物8)是Sirtuin-1的抑制剂,在肥胖诱导的糖尿病和衰老相关疾病中起着重要作用。

  • GC73817 structure
    GC738172-APQC
    CAS: 500271-63-6
    纯度: >98.00%

    2-APQC是一种SIRT3激活剂,Kd值为2.756μM。

  • GC73831 structure
    GC73831ART26.12
    CAS: 2766800-24-0
    纯度: >99.00%

    ART26.12是一种具有抗大麻素特性的口服活性FABP5抑制剂。

  • GC73838 structure
    GC73838TfR-1-IN-1
    CAS: 1643444-62-5
    纯度: >96.00%

    TfR-1-IN-1(化合物C4)是一种具有抗癌活性的转铁蛋白受体1 (TfR-1)抑制剂。

  • GC73903 structure
    GC73903MC3138
    CAS: 1844889-12-8
    纯度: >99.00%

    MC3138是一种选择性SIRT5激活剂。

  • GC73961 structure
    GC73961Fumagilin-105
    CAS: 2410081-58-0
    纯度: >97.00%

    Fumagilin-105是一种靶向自噬的嵌合体(AUTOTAC),可诱导HEK293细胞中MetAP2的p62自寡聚,其DC50值为0.7 μM。

  • GC74342 structure
    GC74342Obtustatin triacetate
    纯度: >99.00%

    Obtustatin triacetate是一种41个残基的非RGD解整合素。

  • GC74346 structure
    GC74346A20FMDV2
    CAS: 932699-03-1
    纯度: >98.00%

    A20FMDV2是一种选择性αvβ6整合素抑制剂(IC50: 3 nM),对αvβ6的选择性比其他rgd定向整合素(αvβ3, αvβ5和α5β1)高1000倍。

  • GC74395 structure
    GC74395Synstatin (92-119)
    CAS: 1259384-47-8
    纯度: >97.00%

    Synstatin (92-119)是一种抑制血管生成和癌细胞侵袭的抗肿瘤药物。

  • GC74401 structure
    GC74401cRGDfK-thioacetyl ester TFA
    纯度: >99.00%

    cRGDfK-thioacetyl ester TFA是一种生物活性多肽分子。cRGDfK肽对整合素具有选择性亲和力。cRGDfK肽可以修饰用于癌症靶向成像的NIR荧光探针。

  • GC74470 structure
    GC74470Veltuzumab
    CAS: 728917-18-8
    纯度: >99.00%

    Veltuzumab (IMMU-106)是一种人源抗cd20单克隆抗体。

  • GC74702 structure
    GC74702YTK-105
    CAS: 774192-20-0
    纯度: >98.00%

    YTK-105是p62 ZZ结构域的配体。

  • GC74710 structure
    GC747102-Methylbutyrylcarnitine chloride
    纯度: >98.00%

    2-Methylbutyrylcarnitine chloride是一种肠道微生物代谢产物,与血小板中的整合素α2β1结合,增强细胞质磷脂酶A2(cPLA2)的活化和血小板的过度反应性。

  • GC91083 structure
    GC91083Tiopronin-Cysteine Disulfide
    CAS: 77591-18-5
    纯度: >95.00%

    一种硫普罗宁的代谢产物。

  • GC91091 structure
    GC91091Spirotetramat-d5
    CAS: 2469007-09-6
    纯度: >99.00%

    一种用于测量斯比罗四唑的内部标准

  • GC91114 structure
    GC91114Xylazine-d6 (CRM)
    CAS: 1228182-53-3

    一种认证参考材料。